Ea6192- A Phase II Study Of Biomarker Driven Early Discontinuation Of Anti-Pd-1 Therapy In Patients With Advanced Melanoma (Pet-Stop)
Posted Date: May 20, 2021
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology
- Type of Study: Drug
The primary goal of this study is to investigate how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery. The primary outcome measured will be event free survival rate.
Criteria:
Must Have Active Advanced Melanoma Defined As Unresectable Stage Iiib-Iv, Must Be Actively Receiving Standard Of Care Anti-Pd-1 Therapy, Currently Be 52 Weeks (+/- 2 Weeks) From Start Of Anti-Pd-1 Therapy, And Have Not Experienced A Toxicity That Prevents
Keywords:
Melanoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com